title: Beneficial effects of diminished production of hydrogen sulfide or carbon monoxide on hypertension and renal injury induced by NO withdrawal.
abstract: OBJECTIVE
  Whether NO, carbon monoxide (CO) and hydrogen sulfide (H2 S) compensate for each other when one or more is depleted is unclear. Inhibiting NOS causes hypertension and kidney injury. Both global depletion of H2 S by cystathionine γ-lyase (CSE) gene deletion and low levels of exogenous H2 S cause hypertension. Inhibiting CO-producing enzyme haeme oxygenase-1 (HO-1) makes rodents hypersensitive to hypertensive stimuli. We hypothesized that combined inhibition of NOS and HO-1 exacerbates hypertension and renal injury, but how combined inhibition of NOS and CSE affect hypertension and renal injury was unclear.
  
  
  METHODS
  Rats were treated with inhibitors of NOS (L-nitroarginine; LNNA), CSE (DL-propargylglycine; PAG), or HO-1 (tin protoporphyrin; SnPP) singly for 1 or 4 weeks or in combinations for 4 weeks.
  
  
  RESULTS
  LNNA always reduced NO, decreased H2 S and increased CO after 4 weeks. PAG abolished H2 S, always enhanced CO and reduced NO, but not when used in combination with other inhibitors. SnPP always increased NO, enhanced H2 S and inhibited CO after 1 week. Rats treated with LNNA, but not PAG and SnPP, rapidly developed hypertension followed by renal dysfunction. LNNA-induced hypertension was ameliorated and renal dysfunction prevented by all additional treatments. Renal HO-1 expression was increased by LNNA in injured tubules and increased in all tubules by all other treatments.
  
  
  CONCLUSIONS
  The amelioration of LNNA-induced hypertension and renal injury by additional inhibition of H2 S and/or CO-producing enzymes appeared to be associated with secondary increases in renal CO or NO production.
authors.affiliation: Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Sebastiaan
authors.initials: S
authors.lastname: Wesseling
authors.forename: Joost O
authors.initials: JO
authors.lastname: Fledderus
authors.forename: Marianne C
authors.initials: MC
authors.lastname: Verhaar
authors.forename: Jaap A
authors.initials: JA
authors.lastname: Joles
mesh_terms: D000480:Alkynes / Q000494:pharmacology; D000818:Animals; D002248:Carbon Monoxide / Q000378:metabolism*; D003542:Cystathionine gamma-Lyase / Q000037:antagonists & inhibitors; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D051547:Heme Oxygenase-1 / Q000037:antagonists & inhibitors; D006862:Hydrogen Sulfide / Q000378:metabolism*; D006973:Hypertension / Q000503:physiopathology*; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D008297:Male; D008665:Metalloporphyrins / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D019335:Nitroarginine / Q000494:pharmacology; D011524:Protoporphyrins / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000480:Alkynes; D008665:Metalloporphyrins; D011524:Protoporphyrins; D019335:Nitroarginine; D009569:Nitric Oxide; C009055:propargylglycine; D002248:Carbon Monoxide; C032628:tin protoporphyrin IX; D019001:Nitric Oxide Synthase; D051547:Heme Oxygenase-1; D003542:Cystathionine gamma-Lyase; D005998:Glycine; D006862:Hydrogen Sulfide